2026 Volume 29 Issue 2 Pages 77-85
Astaxanthin, a carotenoid with strong antioxidant properties, is suggested to have protective effects against chronic conditions such as skin disease, idiopathic epilepsy, and kidney disease. Although several studies have reported the administration of astaxanthin to dogs and cats without significant adverse events, the dosages and durations have varied. In this study, we evaluated the safety of astaxanthin by administering single and repeated oral doses to healthy dogs (n=4) and cats (n=4) regarding physical conditions and blood examination parameters. No serious adverse events were observed in their general condition or blood test results. However, at higher single doses (25 mg/head/day for dogs and 5 mg/head/day for cats), red granules presumed to be undigested astaxanthin were excreted in the feces, suggesting a limit to its absorption. In cats receiving repeated doses of 1 mg/head/day, a statistically significant increase in alkaline phosphatase and BUN was observed, although the values remained within the reference range. The dosages used in this study, particularly 5 mg/head/day for dogs, are considered safe. However, cautious observation of absorption efficiency and potential effects on the liver and kidneys is necessary when administering astaxanthin to animals with underlying diseases or when considering higher doses.